经导管动脉化疗栓塞联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌临床效果
Clinical efficacy of transcatheter arterial chemoembolization combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma
张学贤 1丁雨寒 2李威 1李庆伟 1张君 3段丹 3李永乐 3龙健 3杨继东 1张成龙 1吴鹏 1孙慧娟 3吴耕3
作者信息
- 1. 448000 湖北荆门荆门市人民医院血管介入科
- 2. 荆门市中心医院肿瘤科
- 3. 448000 湖北荆门荆门市人民医院神经介入科
- 折叠
摘要
目的 评价经导管动脉化疗栓塞术(TACE)联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌(HCC)的安全性和有效性.方法 回顾性分析 2020 年 4 月至 2021 年 12 月在荆门市人民医院接受TACE联合仑伐替尼及卡瑞利珠单抗三联治疗或TACE联合仑伐替尼两联治疗的 63 例中晚期HCC患者临床资料,其中三联治疗组 30 例,两联治疗组 33 例.评估记录患者治疗后肿瘤反应、无疾病进展生存期(PFS)、总生存期(OS)及药物不良反应发生率.结果 两组患者中位随访期为 14 个月(4～26 个月).在肿瘤反应方面,三联治疗组与两联治疗组相比,显示出更高的客观缓解率(ORR)(83.3%比 57.6%,P=0.026)、疾病控制率(DCR)(93.3%比 69.7%,P=0.039),可显著延长中位 PFS(8.0 个月比 5.0 个月,P＜0.01)、中位OS(24.0 个月比 12.0 个月,P=0.004).两组患者药物不良反应发生率差异无统计学意义(均P＞0.05).结论 TACE联合仑伐替尼及卡瑞利珠单抗治疗中晚期HCC安全有效.
Abstract
Objective To evaluate the safety and efficacy of transcatheter arterial chemoembolization(TACE)combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma(HCC).Methods The clinical data of a total of 63 patients with advanced HCC,who received TACE combined with lenvatinib and camrelizumab(triple therapy)or TACE combined with lenvatinib(dual therapy)at the Jingmen Municipal People's Hospital of China between April 2020 and December 2021,were retrospectively analyzed.Triple therapy group had 30 patients,and dual therapy group had 33 patients.The post-treatment tumor response,disease progression-free survival(PFS),overall survival(OS),and the incidence of adverse drug reactions were recorded.Results The median follow-up period of the two groups was 14 months(range of 4-26 months).Compared with the dual therapy group,in the triple therapy group the objective response rate(ORR)was remarkably higher(83.3%vs.57.6%,P=0.026),the disease control rate(DCR)was obviously higher(93.3%vs.69.7%,P=0.039),the median PFS was significantly longer(8.0 months vs.5.0 months,P＜0.01),and the median OS was strikingly longer(24.0 months vs.12.0 months,P=0.004).No statistically significant difference in the incidence of adverse drug reactions existed between the two groups(P＞0.05).Conclusion For the treatment of advanced HCC,TACE combined with lenvatinib and camrelizumab is clinically safe and effective.(J Intervent Radiol,2024,32:57-62)
关键词
经导管动脉化疗栓塞术/仑伐替尼/卡瑞利珠单抗/肝细胞癌/疗效/安全性Key words
transcatheter arterial chemoembolization/lenvatinib/camrelizumab/hepatocellular carcinoma/curative effect/safety引用本文复制引用
出版年
2024
NETL
NSTL
万方数据